Sei Investments Co. decreased its position in shares of NuVasive, Inc. (NASDAQ:NUVA) by 1.3% in the 4th quarter, Holdings Channel reports. The firm owned 171,256 shares of the medical device company’s stock after selling 2,277 shares during the quarter. Sei Investments Co.’s holdings in NuVasive were worth $10,017,000 at the end of the most recent quarter.
A number of other institutional investors have also recently added to or reduced their stakes in NUVA. Zions Bancorporation bought a new position in NuVasive during the 3rd quarter worth approximately $160,000. Icon Advisers Inc. Co. bought a new stake in shares of NuVasive in the 3rd quarter valued at $360,000. Crossmark Global Holdings Inc. bought a new stake in shares of NuVasive in the 3rd quarter valued at $427,000. ING Groep NV increased its stake in shares of NuVasive by 23.6% in the 4th quarter. ING Groep NV now owns 7,691 shares of the medical device company’s stock valued at $450,000 after acquiring an additional 1,469 shares in the last quarter. Finally, Legato Capital Management LLC increased its stake in shares of NuVasive by 136.2% in the 3rd quarter. Legato Capital Management LLC now owns 8,741 shares of the medical device company’s stock valued at $485,000 after acquiring an additional 5,041 shares in the last quarter.
Shares of NuVasive, Inc. (NUVA) opened at $47.86 on Friday. NuVasive, Inc. has a 52-week low of $44.62 and a 52-week high of $81.68. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.85 and a quick ratio of 1.51. The stock has a market cap of $2,439.33, a price-to-earnings ratio of 25.32, a P/E/G ratio of 1.34 and a beta of 0.50.
Several analysts have recently weighed in on NUVA shares. Leerink Swann lowered shares of NuVasive from an “outperform” rating to a “market perform” rating in a research note on Thursday, February 1st. Piper Jaffray Companies reiterated a “buy” rating and issued a $90.00 price objective on shares of NuVasive in a research note on Tuesday, January 9th. Wells Fargo & Co lowered shares of NuVasive from an “outperform” rating to a “market perform” rating and set a $65.00 price objective for the company. in a research note on Wednesday, January 17th. Zacks Investment Research upgraded shares of NuVasive from a “hold” rating to a “buy” rating and set a $54.00 price objective for the company in a research note on Monday, February 19th. Finally, Royal Bank of Canada lowered their price objective on shares of NuVasive from $75.00 to $70.00 and set an “outperform” rating for the company in a research note on Friday, November 10th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have assigned a buy rating to the company. NuVasive has a consensus rating of “Buy” and an average price target of $71.19.
Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.
Want to see what other hedge funds are holding NUVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NuVasive, Inc. (NASDAQ:NUVA).
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.